Givastomig
-
Everest Medicines has strategically increased its stake in I-Mab, becoming its largest shareholder
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
-
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
For more DrugTimes bio-news, please follow DrugTimes. Many thanks!
-
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
For more bio-news, please follow DrugTimes. Many thanks!
